NUMI Hit $0.53 Up 86% in One Month
Wednesday, 28 October 2020, 12:17
Yesterday morning, NUMI hit a high of $0.53 per share for a gain of 85.96% from our breakout point alert exactly one month ago on the morning of September 28th at $0.285 per share.
CMPS Featured on CNBC
Friday, 23 October 2020, 21:00
Compass Pathways (CMPS) was featured on CNBC today, causing the stock to gain by $4.19 or 12.25% to close at $38.39 per share. Here is a video of the segment.
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Thursday, 22 October 2020, 16:02
NUMI has just made history by harvesting the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence.
Psychstocks New #1 Pick: RVV
Wednesday, 21 October 2020, 9:00
Psychstocks is extremely excited to announce its new #1 favorite psilocybin biotechnology stock suggestion: Revive Therapeutics (CSE: RVV). Revive also has a U.S. OTC symbol: RVVTF.
Major Psychstocks Announcement Coming
Monday, 19 October 2020, 13:52
Psychstocks is getting ready to announce its #1 favorite psilocybin biotechnology stock suggestion!
CMPS Second Biggest Up Day Since IPO
Wednesday, 14 October 2020, 15:12
Compass Pathways (CMPS) gained by $3.66 or 10.41% yesterday to close at $38.82 per share for its second biggest up day since its IPO less than one month ago.
Washington DC to Vote on Decriminalizing Mushrooms
Tuesday, 13 October 2020, 13:51
On November 3rd, Washington DC will be voting on Initiative 81 to make the enforcement of laws against natural plant medicines among the lowest law enforcement priorities.
PsychStocks Alert: NUMI Hits New 3-Month High!
Thursday, 8 October 2020, 15:11
Our #1 favorite psychstock NUMI is up 10.17% today to a new 3-month high of $0.325 per share!
Learn About Pyschstocks.com and Our Founder
Tuesday, 6 October 2020, 13:00
Thank you for visiting Psychstocks.com an organization that is dedicated to discovering the future leaders of the emerging psychedelic plant medicine industry. Learn about our organization and founder by reading this article.
CMPS Hits New Record High, then Declines Due to Huge Gap Left in Chart
Monday, 5 October 2020, 17:30
Following the release of Citron Research’s bullish report on Compass Pathways (CMPS), the stock gained as much as 28.44% to reach a new record high of $47.29 per share, but only finished the day up by 8.91% to $40.10 per share. We believe Andrew Left made a mistake by releasing his report before the open of trading.
Citron Research Issues $100 Target Price on CMPS
Monday, 5 October 2020, 9:00
Andrew Left’s Citron Research issued a research report today on Compass Pathways (CMPS) giving it a target price of $100 per share.
Oregon to Vote November 3rd on Psilocybin Mushroom Services Program Initiative
Sunday, 4 October 2020, 14:00
On November 3rd, residents of Oregon will vote on Oregon Measure 109, the Psilocybin Mushroom Services Program Initiative of 2020.
NUMI Surpasses Key Breakout Point
Monday, 28 September 2020, 12:38
NUMI has just surpassed its key breakout point while CMPS is now up by 153.94% from its IPO price in only six trading days with its valuation surpassing $1.5 billion!
Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
Thursday, 24 September 2020, 9:00
NUMI has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
Tuesday, 22 September 2020, 8:00
The total gross proceeds from CMPS’s IPO were $146.6 million after sale of additional 1,125,000 ADSs.
COMPASS Pathways announces pricing of upsized initial public offering
Friday, 18 September 2020, 9:00
CMPS raises $127.5 million at IPO price of $17 per ADS.
Psychedelic Research Fundraising Campaign Attracts $30 Million in Donations in 6 Months, Prepares MDMA-Assisted Psychotherapy for FDA Approval
Thursday, 20 August 2020, 9:00
Our friends at the Non-Profit MAPS have successfully raised $30 million through the Capstone Campaign to be used to seek FDA approval of MDMA-assisted psychotherapy for PTSD.
Psychstocks Announces its #1 Favorite Pick of 2020
Thursday, 6 August 2020, 8:00
We are excited to announce Numinus Wellness (TSXV: NUMI) as our #1 Favorite Pick of 2020